Compare PNTG & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PNTG | OPK |
|---|---|---|
| Founded | 2019 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 921.2M |
| IPO Year | 2019 | 2011 |
| Metric | PNTG | OPK |
|---|---|---|
| Price | $33.85 | $1.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $36.50 | $2.28 |
| AVG Volume (30 Days) | 288.6K | ★ 2.3M |
| Earning Date | 05-27-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | N/A |
| EPS | ★ 0.84 | N/A |
| Revenue | ★ $947,705,000.00 | $606,879,000.00 |
| Revenue This Year | $36.42 | N/A |
| Revenue Next Year | $23.99 | N/A |
| P/E Ratio | $40.07 | ★ N/A |
| Revenue Growth | ★ 36.31 | N/A |
| 52 Week Low | $21.18 | $1.11 |
| 52 Week High | $35.00 | $2.04 |
| Indicator | PNTG | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 63.02 | 50.33 |
| Support Level | $26.65 | $1.23 |
| Resistance Level | N/A | $1.27 |
| Average True Range (ATR) | 1.57 | 0.04 |
| MACD | 0.14 | 0.00 |
| Stochastic Oscillator | 83.59 | 75.00 |
Pennant Group Inc is engaged in providing healthcare services to patients of all ages, including the growing senior population, in the United States. It operates in multiple lines of business including home health, hospice, and senior living which includes the company's assisted living, independent living, and memory care communities across Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The company generates majority of its revenue from home health and hospice services segment, which includes its home health, hospice and home care businesses.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.